Group 1 - The company held its 24th meeting of the fifth board of directors on February 2, 2026, to discuss urgent matters, with all five directors present and in compliance with relevant laws and regulations [2][3][4] - The board approved a proposal to lower the conversion price of the "Meinuo Convertible Bonds" from 25.68 yuan per share to 21.28 yuan per share, effective from February 4, 2026 [3][11][18] Group 2 - The "Meinuo Convertible Bonds" will be suspended from conversion on February 3, 2026, and will resume on February 4, 2026 [8][11] - The company issued 520 million yuan worth of convertible bonds in January 2021, with an initial conversion price of 37.47 yuan per share [8][11] - The conversion price has been adjusted multiple times since issuance, with the most recent adjustment being from 25.68 yuan to 21.28 yuan due to stock price performance [9][10][15][18] Group 3 - The adjustment to the conversion price was triggered by the stock price being below 90% of the current conversion price for at least 15 out of 30 consecutive trading days [15][16] - The board's decision to lower the conversion price was aimed at supporting the company's long-term development and optimizing its capital structure [16][18]

Group 1 - The company has approved a share repurchase plan to buy back its issued A-shares using its own and/or self-raised funds, with a maximum price of RMB 42.00 per share and a total fund amount between RMB 25 million and RMB 50 million [1] - The estimated number of shares to be repurchased is approximately 595,238 to 1,190,476 shares, which accounts for about 0.78% to 1.56% of the company's total share capital [1] - The implementation period for the share repurchase is within twelve months from the board's approval date [1] Group 2 - The company has obtained a loan commitment from China Construction Bank for the share repurchase, with a maximum loan amount not exceeding RMB 45 million [3] - The loan term is set for three years, specifically for the purpose of repurchasing the company's listed shares [4][5] - The loan commitment becomes effective upon signature and seal by the bank's authorized representative and is valid until January 29, 2027 [5] Group 3 - The loan commitment provides financing support for the share repurchase, but does not guarantee the total repurchase amount, which will be determined based on actual funds used at the end of the repurchase [6] - The company will implement the repurchase plan based on market conditions and will fulfill its information disclosure obligations as required by laws and regulations [6]

Industry Overview - The price of niacinamide has been continuously rising, with a reported price of 39.5 yuan per kilogram on February 2, reflecting an increase of approximately 14.5% since early January 2026 [1] - Niacinamide is diversely applied in three major sectors: food, pharmaceuticals, and cosmetics, due to its nutritional enhancement and functional characteristics [1] - In the food industry, niacinamide is widely added to daily foods such as grains and dairy products to meet consumer demands for nutritional fortification [1] - In the cosmetics sector, its excellent anti-aging and whitening effects have made it a star ingredient in skincare products, included in high-end lines like serums and creams [1] - The pharmaceutical industry is seeing deepening applications of niacinamide in disease treatment and health care [1] - The market size for niacinamide is expanding, driven by global population aging trends and increasing consumer demand for health and beauty products [1] Company Insights - Brother Technology focuses on pharmaceutical food and specialty chemicals, with an annual production capacity of 8,000 tons for niacinamide products [2] - Baihe Co., Ltd. is a national high-tech enterprise specializing in the research, production, and sales of nutritional health foods, with its NMN products involving niacinamide [2]

海思科（002653）(002653.SZ)发布公告，近日，公司收到部分5%以上股东之一致行动人郝聪梅女士、 杨飞女士《关于减持公司股份计划的告知函》，郝聪梅、杨飞计划自公告披露之日起十五个交易日后的 三个月内，通过大宗交易或集中竞价方式减持公司股份合计不超过1000万股，减持比例合计不超过公司 总股本的0.89%。 ...

Core Insights - The report highlights significant target price increases for several companies, with 百利天恒 leading at 375.97%, followed by 泽璟制药 at 88.56% and 长城汽车 at 83.66% [1][2]. Target Price Increases - 百利天恒 (CITIC Securities) has a target price increase of 375.97%, with a latest price of 1322.00 CNY [2]. - 泽璟制药 (Huatai Securities) shows a target price increase of 88.56%, with a latest price of 166.16 CNY [2]. - 长城汽车 (CITIC Securities) has a target price increase of 83.66%, with a latest price of 38.00 CNY [2]. - Other notable increases include 工业富联 (Huatai Securities) at 73.31% and 宁德时代 (Dongwu Securities) at 71.71% [2]. Broker Recommendations - A total of 265 companies received broker recommendations from January 26 to February 1, with 青岛银行 receiving the highest number at 8 recommendations [3]. - 先导智能 and 万辰集团 each received 5 recommendations [3]. Rating Adjustments - During the same period, 8 companies had their ratings upgraded, including 上海家化 (Guolian Minsheng Securities) from "Hold" to "Recommend" [4]. - 中兴通讯 (Dongguan Securities) was upgraded from "Cautious Recommend" to "Buy" [4]. - 特变电工 (Huatai Securities) was upgraded from "Hold" to "Buy" [4]. Rating Downgrades - Two companies had their ratings downgraded, including 金辰股份 (Zheshang Securities) from "Buy" to "Hold" [5]. - 华设集团 (Guotai Junan Securities) was downgraded from "Buy" to "Hold" [5]. First Coverage - A total of 75 instances of first coverage were reported, with 陕西旅游 receiving a "Outperform Industry" rating from China International Capital Corporation [6]. - 柏楚电子 was rated "Hold" by Guotai Junan Securities, and 博汇纸业 received a "Buy" rating from Guohai Securities [6].

智通财经APP讯，润都股份(002923.SZ)发布股价异动公告称，公司目前有1类创新药(化学药)盐酸去甲 乌药碱注射液(规格：2ml:2.5mg)及其原料药，其药品审评工作正在有序进行。创新药具有研发周期 长，投入大，风险高的特点，药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不 确定性，短期内也不会对公司业绩产生重大影响。 ...

格隆汇2月2日丨西点药业(301130.SZ)公布，近日，公司取得中国建设银行股份有限公司长春西安大路 支行出具的《贷款承诺书》，承诺为公司本次回购股份提供专项贷款支持。主要内容如下：1、贷款银 行：中国建设银行股份有限公司长春西安大路支行。2、承诺贷款额度：最高额不超过人民币肆仟伍佰 万元整。3、贷款期限：3年。4、贷款用途：回购已发行上市股票。5、贷款承诺书自建设银行法定代表 人或授权代理人签字并加盖建设银行公章之日（即签发之日）起生效，有效期截至2027年1月29日。 ...

Group 1 - The company, Shanghai Yizhong, reported a total operating revenue of 317,076,818.03 yuan for the year 2025, representing a year-on-year increase of 82.72% [2] - The net profit attributable to the parent company's shareholders reached 64,131,993.35 yuan, showing a significant year-on-year growth of 819.42% [2]

（文章来源：证券日报） 证券日报网讯 2月2日，东阳光在互动平台回答投资者提问时表示，公司已建立了规范的财务、会计管 理内部控制制度，拥有完善的财务管理体系，并严格遵守上市公司财务独立核算规定。随着公司不断的 发展，公司会不断提高财务数字化、智能化的水平。 ...

Group 1 - The company Huabei Pharmaceutical announced that as of the disclosure date, the total amount of external guarantees provided by the company and its controlling subsidiaries is approximately 1.644 billion yuan, accounting for 30.5% of the audited net assets attributable to ordinary shareholders for the year 2024 [1] - Among the total guarantees, the company provided guarantees totaling approximately 1.554 billion yuan for its controlling subsidiaries, which represents 28.83% of the audited net assets attributable to ordinary shareholders for 2024 [1] - The amount of guarantees provided to external units not included in the consolidated financial statements is 90 million yuan, accounting for 1.67% of the audited net assets attributable to ordinary shareholders for 2024 [1] Group 2 - The automotive sales giant Baolide, known for selling luxury cars such as Rolls-Royce and Porsche, is currently undergoing bankruptcy liquidation, with its headquarters in Hangzhou now vacant and its subsidiary in Yiwu sealed [1]